Infliximab treatment for severe psoriasis in a patient with active hepatitis B virus infection

Conde‐Taboada, Alberto; Muñoz, Javier Pedraz; Muñoz, Lucía Campos; López‐Bran, Eduardo

doi:10.1016/j.jaad.2008.09.057

Cited by 20 publications

(20 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The published experience is limited, coming from the fields of gastroenterology and rheumatology and is based on sporadic case reports and small retrospective studies. To date, 40 cases of patients treated with anti‐TNFα agents in the context of chronic HBV infection have been reported 7–18 . Viral reactivation was detected in several cases, mostly under treatment with infliximab 7,11,12,16–18 .…”

Section: Discussionmentioning

confidence: 99%

“…To date, 40 cases of patients treated with anti‐TNFα agents in the context of chronic HBV infection have been reported 7–18 . Viral reactivation was detected in several cases, mostly under treatment with infliximab 7,11,12,16–18 . However, fulminant hepatic failure leading to liver transplantation or even death was observed in two cases 16,17 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Safety of anti‐tumour necrosis factor‐α agents in psoriasis patients who were chronic hepatitis B carriers: a retrospective report of seven patients and brief review of the literature

Fotiadou

Lazaridou

Ioannides

2011

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Safety of anti‐tumour necrosis factor‐α agents in psoriasis patients who were chronic hepatitis B carriers: a retrospective report of seven patients and brief review of the literature

Fotiadou

Lazaridou

Ioannides

2011

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Several small case series in HBsAg carriers with psoriasis have been published (Table IV). 28,52,[95][96][97][98][99] In one, 3 patients were treated with adalimumab, 3 with etanercept, and 1 with infliximab. 28 All were given antiviral prophylaxis with lamivudine and none developed reactivation of hepatitis B during 6 to 24 months.…”

Section: Clinical Experiences With Tnf-alpha Inhibitors In Patients Wmentioning

confidence: 99%

Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: A review and recommendations for management

Abramson¹,

Menter²,

Perrillo³

2012

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

“…The Spanish REPENTINA study showed that no single drug was specifically involved, and the risk seems to be associated with the intensity of immunosuppression [39,40] . Case reports of HBV exacerbation in severe psoriasis patients have also been published [41] . In a recent review in patients with rheumatic, digestive, and dermatologic autoimmune diseases, treated with any of the anti-TNF inhibitors, by Pérez-Alvarez et al [42] HBV reactivation was observed in 39% of hepatitis B carriers in hepatitis B carriers.…”

Section: Hbv Reactivations In Patients With Inflammatory Diseasesmentioning

confidence: 99%

Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: When and how to apply prophylaxis, with a special focus on corticosteroid therapy

López-Serrano

Briongos

Alonso

et al. 2015

WJH

View full text Add to dashboard Cite

Currently immunosuppressive and biological agents are used in a more extensive and earlier way in patients with inflammatory bowel disease, rheumatic or dermatologic diseases. Although these drugs have shown a significant clinical benefit, the safety of these treatments is a challenge. Hepatitis B virus (HBV) reactivations have been reported widely, even including liver failure and death, and it represents a deep concern in these patients. Current guidelines recommend to preemptive therapy in patients with immunosuppressants in general, but preventive measures focused in patients with corticosteroids and inflammatory diseases are scarce. Screening for HBV infection should be done at diagnosis. The patients who test positive for hepatitis B surface antigen, but do not meet criteria for antiviral treatment must receive prophylaxis before undergoing immunosuppression, including corticosteroids at higher doses than prednisone 20 mg/d during more than two weeks. Tenofovir and entecavir are preferred than lamivudine because of their better resistance profile in long-term immunosuppressant treatments. There is not a strong evidence, to make a general recommendation on the necessity of prophylaxis therapy in patients with inflammatory diseases that are taking low doses of corticosteroids in short term basis or low systemic bioavailability corticosteroids such as budesonide or beclomethasone dipropionate. In these cases regularly HBV DNA monitoring is recommended, starting early antiviral therapy if DNA levels begin to rise. In patients with occult or resolved hepatitis the risk of reactivation is much lower, and excepting for Rituximab treatment, the prophylaxis is not necessary. Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: When and how to apply prophylaxis, with a special focus on corticosteroid therapyCore tip: Few reviews have been published including data of the three more common inflammatory diseases that require immunosuppressive therapy: inflammatory bowel disease, rheumatic and dermatologic diseases. This paper is focused on the risk of reactivation of hepatitis B virus under immunosuppressants, and particularly corticosteroids. Although most of the guidelines do not specify the necessity of prophylaxis in case of monotherapy with corticosteroids, the specialists responsible of these patients are usually concerned about this issue. Moreover, the risk with low systemic bioavailability new corticosteroids has not been evaluated in previous reviews. This work summarizes the evidence of VHB reactivation in patients with inflammatory diseases: when and how to apply prophylaxis, with a special focus on "new" and "old" steroids.López-Serrano P, de la Fuente Briongos E, Carrera-Alonso E, Pérez-Calle JL, Fernández Rodríguez C. Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: When and how to apply prophylaxis, with a special focus on corticosteroid therapy.

show abstract

Infliximab treatment for severe psoriasis in a patient with active hepatitis B virus infection

Cited by 20 publications

References 15 publications

Safety of anti‐tumour necrosis factor‐α agents in psoriasis patients who were chronic hepatitis B carriers: a retrospective report of seven patients and brief review of the literature

Safety of anti‐tumour necrosis factor‐α agents in psoriasis patients who were chronic hepatitis B carriers: a retrospective report of seven patients and brief review of the literature

Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: A review and recommendations for management

Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: When and how to apply prophylaxis, with a special focus on corticosteroid therapy

Contact Info

Product

Resources

About